JOHN FOREYT to Blood Glucose
This is a "connection" page, showing publications JOHN FOREYT has written about Blood Glucose.
Connection Strength
0.452
-
A Narrative Review of Diabetes Group Visits in Low-Income and Underserved Settings. Curr Diabetes Rev. 2019; 15(5):372-381.
Score: 0.109
-
Inflammatory markers are elevated in overweight Mexican-American children. Int J Pediatr Obes. 2007; 2(4):235-41.
Score: 0.047
-
Weight loss with meal replacement and meal replacement plus snacks: a randomized trial. Int J Obes (Lond). 2005 Sep; 29(9):1107-14.
Score: 0.043
-
Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial. Diabetes Care. 2014 Dec; 37(12):3227-34.
Score: 0.040
-
Implications of Look AHEAD for clinical trials and clinical practice. Diabetes Obes Metab. 2014 Dec; 16(12):1183-91.
Score: 0.040
-
The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med. 2013 Mar; 126(3):236-42, 242.e1-2.
Score: 0.036
-
Genetic bottlenecks, perceived racism, and hypertension risk among African Americans and first-generation African immigrants. J Hum Hypertens. 2001 May; 15(5):341-51.
Score: 0.032
-
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010 Sep 27; 170(17):1566-75.
Score: 0.031
-
Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care. 2018 08; 41(8):1590-1599.
Score: 0.026
-
Obese Mexican American children have elevated MCP-1, TNF-a, monocyte concentration, and dyslipidemia. Pediatrics. 2012 May; 129(5):e1180-6.
Score: 0.017
-
Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. Clin Trials. 2009 Oct; 6(5):416-29.
Score: 0.014
-
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002 Jul; 25(7):1123-8.
Score: 0.009
-
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20; 281(3):235-42.
Score: 0.007